Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.

Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Abstract Text:

Cordula M Wolf,Michael Arad,Ferhaan Ahmad,Atsushi Sanbe,Scott A Bernstein,Okan Toka,Tetsuo Konno,Gregory Morley,Jeffrey Robbins,J G Seidman,Christine E Seidman,Charles I Berul,Cordula M Wolf,Michael Arad,Ferhaan Ahmad,Atsushi Sanbe,Scott A Bernstein,Okan Toka,Tetsuo Konno,Gregory Morley,Jeffrey Robbins,J G Seidman,Christine E Seidman,Charles I Berul,

BACKGROUND: PRKAG2 mutations cause glycogen-storage cardiomyopathy, ventricular preexcitation, and conduction system degeneration. A genetic approach that utilizes a binary inducible transgenic system was used to investigate the disease mechanism and to assess preventability and reversibility of disease features in a mouse model of glycogen-storage cardiomyopathy. METHODS AND RESULTS: Transgenic (Tg) mice expressing a human N488I PRKAG2 cDNA under control of the tetracycline-repressible alpha-myosin heavy chain promoter underwent echocardiography, ECG, and in vivo electrophysiology studies. Transgene suppression by tetracycline administration caused a reduction in cardiac glycogen content and was initiated either prenatally (Tg(OFF(E-8 weeks))) or at different time points during life (Tg(OFF(4-16 weeks)), Tg(OFF(8-20 weeks)), and Tg(OFF(>20 weeks))). One group never received tetracycline, expressing transgene throughout life (Tg(ON)). Tg(ON) mice developed cardiac hypertrophy followed by dilatation, ventricular preexcitation involving multiple accessory pathways, and conduction system disease, including sinus and atrioventricular node dysfunction. CONCLUSIONS: Using an externally modifiable transgenic system, cardiomyopathy, cardiac dysfunction, and electrophysiological disorders were demonstrated to be reversible processes in PRKAG2 disease. Transgene suppression during early postnatal development prevented the development of accessory electrical pathways but not cardiomyopathy or conduction system degeneration. Taken together, these data provide insight into mechanisms of cardiac PRKAG2 disease and suggest that glycogen-storage cardiomyopathy can be modulated by lowering glycogen content in the heart.

Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Publishing Authors By Initials

CM Wolf,M Arad,F Ahmad,A Sanbe,SA Bernstein,O Toka,T Konno,G Morley,J Robbins,JG Seidman,CE Seidman,CI Berul,CM Wolf,M Arad,F Ahmad,A Sanbe,SA Bernstein,O Toka,T Konno,G Morley,J Robbins,JG Seidman,CE Seidman,CI Berul,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Circulation

VOLUME: 117

Page Numbers: 144-54

Journal Abbreviation: Circulation

ISSN: 1524-4539

DAY: 24

MONTH: 12

YEAR: 2007

Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 147763

Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.

AFFILIATION: Department of Cardiology, Children's Hospital Boston, Boston, MA 02115, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Circulation

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations Related Publications

• How revealing are insertable loop recorders in pediatrics?
• Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations.
• Ventricular arrhythmias: when to worry.